CLDI 8-K: SEC filing
Filed with the SEC on · accession 0001193125-26-460816
CLDI filed a 8-K (current report) with the SEC on Nov 13, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Summary of the filing
Calidi Biotherapeutics furnished a press release announcing its financial results for the third quarter ended September 30, 2026, along with certain other corporate developments.
Key details
✦ Ask GOAX AI about this filing — what it means for CLDI, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for CLDI?
Click hereFrequently asked questions
What did CLDI file with the SEC on Nov 13, 2026?
CLDI filed a 8-K (SEC filing). Calidi Biotherapeutics furnished a press release announcing its financial results for the third quarter ended September 30, 2026, along with certain other corporate developments.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other CLDI SEC filings
Get alerts when CLDI files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days